RT Journal Article
SR Electronic
T1 Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1457
OP 1460
DO 10.2967/jnumed.120.258434
VO 62
IS 10
A1 Minseok Suh
A1 Hyung-Jun Im
A1 Hyun Gee Ryoo
A1 Keon Wook Kang
A1 Jae Min Jeong
A1 Sneha Prakash
A1 Sanjana Ballal
A1 Madhav P. Yadav
A1 Chandrasekhar Bal
A1 Chang Wook Jeong
A1 Cheol Kwak
A1 Gi Jeong Cheon
YR 2021
UL http://jnm.snmjournals.org/content/62/10/1457.abstract
AB 68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)–targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results: 68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging.